Heart failure & cardiomyopathies
Prevalence of Transthyretin Amyloid Cardiomyopathy in Pacemaker Patients
Authors' conclusion
The prevalence of ATTR-CM in elderly patients with PM and LVH on echocardiography was 19%.
Study context
- Population
- Patients ≥65 years with permanent pacemaker from an out-patient pacemaker clinic58 with left ventricular hypertrophy (LVH)
- Participants
- 128 patients
- Outcome
- Prevalence of ATTR-CM
Methodological detailsprospective, single-centre, Echocardiography at pacemaker visit; referral to 99mTc-DPD-scintigraphy and blood samples if septum thickness ≥12 mm
- Prospective
- Single-centre
- Echocardiography at pacemaker visit; referral to 99mTc-DPD-scintigraphy and blood samples if septum thickness ≥12 mm
Main finding
As reported in the abstract
ATTR-CM among patients with LVH
19%
ATTR-CM in total cohort
9%
Patients with DPD-scintigraphy based ATTR-CM diagnosis
11
Observational data: associations, not effects.
Further findings
Characteristics of patients with vs without ATTR-CM
- Higher cardiac biomarker concentrations with ATTR-CM
- P < 0.001
- Higher E/E' with ATTR-CM
- P = 0.001
- Lower global longitudinal strain with ATTR-CM
- P = 0.003
- More HF symptoms with ATTR-CM
- P = 0.001
Original publication
Prevalence of Transthyretin Amyloid Cardiomyopathy in Pacemaker Patients. ESC Heart Fail. Published 10 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →